AbbVie Inc. (ABBV19)
Stock Exchange of Thailand · Thailand · prices in THB · close of 27 Oct 2026
Key indicators
| Last close | THB 9.650 |
|---|---|
| 52-week range | 6.250 – 9.800 |
| Return, 1 month / 3 months | +9.6% / +10.9% |
| Return, 1 year / 3 years | +32.7% / – |
| Trend | Uptrend |
| RSI (14) | 68 |
| Volatility (1 year) | 29.8% |
| Worst drawdown (1 year) | -19.3% |
| Average daily value traded | 0.44M THB |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
AbbVie is a biopharmaceutical company that discovers, develops and markets medicines for chronic and complex conditions. Its products include treatments for immune and inflammatory diseases, blood cancers, neurological disorders and eye conditions, along with aesthetic products such as Botox. It serves patients and healthcare providers through prescription medicines and medical aesthetics, and it is based in North Chicago, Illinois, in the United States.
AbbVie Inc. trades under the code ABBV19 on the Stock Exchange of Thailand in Thailand, with its price quoted in Thai baht (THB). Our dividend records, which start in 2019, show payments in 2 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
AbbVie Inc. (ABBV19) trades on the Stock Exchange of Thailand in Thailand. It last closed at THB 9.650 on 27 October 2026.
Its price-based Market X-Ray is 72 out of 100 (a strong price profile), ranking 173 of 1,349 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 32.7% and over the last three months it rose 10.9%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Stock Exchange of Thailand
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 90 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 26.5% | ||
| From 52-week high | -0.5% | ||
| Momentum | 81 · Strong | Rising faster than most stocks on this exchange. | |
| 3-month return | 10.9% | ||
| 6-month return | 51.3% | ||
| 12-month return, skipping the last month | 21.1% | ||
| Stability (higher is calmer) | 67 · Fair | Typical risk for this exchange. | |
| Volatility, 1 year (lower is calmer) | 29.8% | ||
| Worst drawdown, 1 year (smaller is calmer) | -19.3% | ||
| Liquidity | 37 · Weak | Thinly traded: prices can jump and exits can be hard. | |
| Average daily value traded | 0.44M THB | ||
| Zero-volume days | 1.7% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 2 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
- Momentum: Rising faster than most stocks on this exchange.
Weak spots
- Liquidity: Thinly traded: prices can jump and exits can be hard.
Returns
| 1 week | +0.5% |
|---|---|
| 1 month | +9.6% |
| 3 months | +10.9% |
| 6 months | +51.3% |
| 1 year | +32.7% |
| 3 years | – |
| 5 years | – |
Signals
| 50-day / 200-day average | 8.806 / 7.628 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.199 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 15 Oct 2026 | USD 0.0480 |
| 15 Jul 2026 | USD 0.0476 |
| 16 Apr 2026 | USD 0.0455 |
| 16 Jan 2026 | USD 0.0472 |
| 15 Oct 2025 | USD 0.0439 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Stock Exchange of Thailand; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.